Clopivas - Clopivas is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is marketed by Bristol-Myers Squibb and Sanofi-Aventis under the trade name Plavix, by Sun Pharmaceuticals under the trade name Clopilet, by Ranbaxy Laboratories under the trade name Ceruvin, and under the name "Clavix" by Intas Pharmaceuticals. It works by irreversibly inhibiting a receptor called P2Y12. Adverse effects include hemorrhage.
Clopivas is a blood-thinning medicine. It prevents special cells in the blood -- the platelets -- from sticking to each other. This reduces the risk of harmful blood clots forming. Blood clots that form in a blood vessel inside the heart or brain can cause a heart attack or a stroke. Clopivas is used to reduce the risk of heart attacks and strokes in people at high risk. This includes people who have had a heart attack or stroke before and are at risk of getting another one. It also includes people with blood circulation problems that may increase their chances of getting a heart attack or stroke. Clopivas is also used together with aspirin to prevent blood clots in people who have had stents inserted into their heart arteries. Clopivas may also be used to treat other conditions such as peripheral arterial disease (where there is some blockage or narrowing of arteries) or heart disease.
Indications: thromboembolic disorders
Acute Coronary Syndrome (ACS) * For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization,this medicine has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. * For patients with ST-elevation myocardial infarction (STEMI), this medicine has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary percutaneous coronary intervention is unknown. The optimal duration of this medicine therapy in ACS is unknown. Recent MI, Recent Stroke, or Established Peripheral Arterial DiseaseFor patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, this medicine has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death.
Indications: Reduction of athero-sclerotic events (MI, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent MI or established peripheral arterial disease.